Pattern recognition receptors in immune disorders affecting the skin

Journal of Innate Immunity

Volumn 4, Issue 3, 2012, Pages 225-240

  De Koning, Heleen D ^a,b,c   Simon, Anna ^a,c   Zeeuwen, Patrick L J M ^a,b   Schalkwijk, Joost ^a,b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c N4i Centre for Immunodeficiency and Autoinflammation   (Netherlands)

Author keywords

Autoimmunity; Epithelium; Host defense; Immune response; Pathogen associated molecular patterns; Pattern recognition receptors; Skin; Toll like receptor

Indexed keywords

CALCINEURIN INHIBITOR; CHLOROQUINE; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOMODULATING AGENT; LOXORIBINE; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; BEHCET DISEASE; BLAU SYNDROME; CINCA SYNDROME; GOUT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOLOGY; NLRP12 ASSOCIATED PERIODIC SYNDROME; PRIORITY JOURNAL; PSEUDOGOUT; PSORIASIS; REVIEW; ROSACEA; SARCOIDOSIS; SCHNITZLER SYNDROME; SKIN ALLERGY; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VITILIGO;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; SKIN; SKIN DISEASES; SKIN NEOPLASMS;

EID: 84859918469     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000335900     Document Type: Review

References (157)

1. Hoffman HM, Wanderer AA: Inflammasome and IL-1beta-mediated disorders. Curr Allergy Asthma Rep 2010; 10: 229-235.
2. Lachmann HJ, Quartier P, So A, Hawkins PN: The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum 2011; 63: 314-324.
3. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nunez G, Yodoi J, Kahn SE, Lavelle EC, O'Neill LA: Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
4. Masters SL, Latz E, O'Neill LA: The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med 2011; 3: 81ps17.
5. Menu P, Vince JE: The NLRP3 inflammasome in health and disease: The good, the bad and the ugly. Clin Exp Immunol 2011; 166: 1-15.
6. Kawai T, Akira S: The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21: 317-337.
7. Carneiro LA, Magalhaes JG, Tattoli I, Philpott DJ, Travassos LH: Nod-like proteins in inflammation and disease. J Pathol 2008; 214: 136-148. (Pubitemid 351160152)
8. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G: An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10: 266-272.
9. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES: AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458: 509-513.
10. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA: AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458: 514-518.
11. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, Sirois CM, Jin T, Latz E, Xiao TS, Fitzgerald KA, Paludan SR, Bowie AG: IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010; 11: 997-1004.
12. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschlager N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J: Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol 2010; 11: 63-69.
13. Guttman-Yassky E, Nograles KE, Krueger JG: Contrasting pathogenesis of atopic dermatitis and psoriasis. I. Clinical and pathologic concepts. J Allergy Clin Immunol 2011; 127: 1110-1118.
14. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009; 361: 496-509.
15. de Koning HD, Rodijk-Olthuis D, Van Vlijmen-Willems IM, Joosten LA, Netea MG, Schalkwijk J, Zeeuwen PL: A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: Upregulation of dectin-1 in psoriasis. J Invest Dermatol 2010; 130: 2611-2620.
16. Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, Cogen AL, Gallo RL: TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011; 131: 688-697.
17. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L: Normal keratinocytes express Tolllike receptors (TLRs) 1, 2 and 5: Modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003; 148: 670-679. (Pubitemid 36629744)
18. Begon E, Michel L, Flageul B, Beaudoin I, Jean-Louis F, Bachelez H, Dubertret L, Musette P: Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur J Dermatol 2007; 17: 497-506. (Pubitemid 350207160)
19. Miller LS, Sorensen OE, Liu PT, Jalian HR, Eshtiaghpour D, Behmanesh BE, Chung W, Starner TD, Kim J, Sieling PA, Ganz T, Modlin RL: TGF-alpha regulates TLR expression and function on epidermal keratinocytes. J Immunol 2005; 174: 6137-6143. (Pubitemid 40663803)
20. Kollisch G, Kalali BN, Voelcker V, Wallich R, Behrendt H, Ring J, Bauer S, Jakob T, Mempel M, Ollert M: Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 2005; 114: 531-541. (Pubitemid 40478147)
21. Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C: Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006; 45: 1464-1465. (Pubitemid 44869771)
22. Patel U, Mark NM, Machler BC, Levine VJ: Imiquimod 5% cream induced psoriasis: A case report, summary of the literature and mechanism. Br J Dermatol 2011; 164: 670-672.
23. Wu JK, Siller G, Strutton G: Psoriasis induced by topical imiquimod. Australas J Dermatol 2004; 45: 47-50. (Pubitemid 38315850)
24. Rajan N, Langtry JA: Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006; 31: 140-141.
25. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ, Gilliet M: Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143. (Pubitemid 41002916)
26. Garcia-Lora E, Tercedor J, Massare E, Lopez-Nevot MA, Skiljo M, Garcia-Mellado V: Interferon-induced psoriasis in a patient with chronic hepatitis C. Dermatology 1993; 187: 280. (Pubitemid 23333941)
27. Ladoyanni E, Nambi R: Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol 2005; 4: 221-222.
28. Kowalzick L: Psoriasis flare caused by recombinant interferon beta injections. J Am Acad Dermatol 1997; 36: 501. (Pubitemid 27131991)
29. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182: 5836-5845.
30. Prens EP, Kant M, van Dijk G., van der Wel LI, Mourits S, van der Fits L: IFN-alpha enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: Relevance for psoriasis. J Invest Dermatol 2008; 128: 932-938. (Pubitemid 351374290)
31. Zhu K, Yin X, Tang X, Zhang F, Yang S, Zhang X: Meta-analysis of NOD2/CARD15 polymorphisms with psoriasis and psoriatic arthritis. Rheumatol Int 2011, E-pub ahead of print.
32. Netea MG, Marodi L: Innate immune mechanisms for recognition and uptake of Candida species. Trends Immunol 2010; 31: 346-353.
33. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schroder JM, Liu YJ, Gilliet M: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569. (Pubitemid 47525141)
34. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Goss C, Anz D, Simanski M, Glaser R, Harder J, Hornung V, Gallo RL, Ruzicka T, Besch R, Schauber J: Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011; 3: 82ra38.
35. de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk, Blokx W, Dogan A, Hiemstra PS, van de Kerkhof PC, Schalkwijk J: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005; 125: 1163-1173.
36. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160.
37. Maintz L, Novak N: Modifications of the innate immune system in atopic dermatitis. J Innate Immun 2011; 3: 131-141.
38. Baker BS: The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006; 144: 1-9.
39. Vu AT, Baba T, Chen X, Le TA, Kinoshita H, Xie Y, Kamijo S, Hiramatsu K, Ikeda S, Ogawa H, Okumura K, Takai T: Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 2010; 126: 985-993.
40. Oh DY, Schumann RR, Hamann L, Neumann K, Worm M, Heine G: Association of the toll-like receptor 2 A-16934T promoter polymorphism with severe atopic dermatitis. Allergy 2009; 64: 1608-1615.
41. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, Klotz M, Werfel T, Herz U, Heeg K, Neumaier M, Renz H: The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004; 113: 565-567. (Pubitemid 38338967)
42. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA: A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68: 6398-6401.
43. Niebuhr M, Lutat C, Sigel S, Werfel T: Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis. Allergy 2009; 64: 1580-1587.
44. Weidinger S, Novak N, Klopp N, Baurecht H, Wagenpfeil S, Rummler L, Ring J, Behrendt H, Illig T: Lack of association between Tolllike receptor 2 and Toll-like receptor 4 polymorphisms and atopic eczema. J Allergy Clin Immunol 2006; 118: 277-279. (Pubitemid 43946482)
45. Hoffjan S, Stemmler S, Parwez Q, Petrasch-Parwez E, Arinir U, Rohde G, Reinitz-Rademacher K, Schultze-Werninghaus G, Bufe A, Epplen JT: Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet 2005; 6: 34.
46. Antiga E, Volpi W, Torchia D, Fabbri P, Caproni M: Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis. Clin Exp Dermatol 2011; 36: 235-241.
47. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J, Hagemann T, Diaz-Lacava A, Baurecht HJ, Klopp N, Wagenpfeil S, Behrendt H, Bieber T, Ring J, Illig T, Weidinger S: Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007; 62: 766-772. (Pubitemid 46934363)
48. Weidinger S, Klopp N, Rummler L, Wagenpfeil S, Novak N, Baurecht HJ, Groer W, Darsow U, Heinrich J, Gauger A, Schafer T, Jakob T, Behrendt H, Wichmann HE, Ring J, Illig T: Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol 2005; 116: 177-184. (Pubitemid 40909765)
49. Kabesch M, Peters W, Carr D, Leupold W, Weiland SK, von Mutius E: Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. J Allergy Clin Immunol 2003; 111: 813-817. (Pubitemid 36470254)
50. Macaluso F, Nothnagel M, Parwez Q, Petrasch-Parwez E, Bechara FG, Epplen JT, Hoffjan S: Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis. Exp Dermatol 2007; 16: 692-698. (Pubitemid 47079600)
51. Ribbing C, Engblom C, Lappalainen J, Lindstedt K, Kovanen PT, Karlsson MA, Lundeberg L, Johansson C, Nilsson G, Lunderius-Andersson C, Scheynius A: Mast cells generated from patients with atopic eczema have enhanced levels of granule mediators and an impaired Dectin-1 expression. Allergy 2011; 66: 110-119.
52. Martin SF, Dudda JC, Bachtanian E, Lembo A, Liller S, Durr C, Heimesaat MM, Bereswill S, Fejer G, Vassileva R, Jakob T, Freudenberg N, Termeer CC, Johner C, Galanos C, Freudenberg MA: Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med 2008; 205: 2151-2162.
53. Ptak W, Bryniarski K, Ptak M, Majewska M, Gamian A, Lobo FM, Szczepanik M: Tolllike receptor ligands reverse suppression of contact hypersensitivity reactions induced by epicutaneous immunization with protein antigen. Int Arch Allergy Immunol 2006; 139: 188-200. (Pubitemid 43289503)
54. Schmidt M, Raghavan B, Muller V, Vogl T, Fejer G, Tchaptchet S, Keck S, Kalis C, Nielsen PJ, Galanos C, Roth J, Skerra A, Martin SF, Freudenberg MA, Goebeler M: Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010; 11: 814-819.
55. Watanabe H, Gaide O, Petrilli V, Martinon F, Contassot E, Roques S, Kummer JA, Tschopp J, French LE: Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007; 127: 1956-1963. (Pubitemid 47075373)
56. Arthur JC, Lich JD, Ye Z, Allen IC, Gris D, Wilson JE, Schneider M, Roney KE, O'Connor BP, Moore CB, Morrison A, Sutterwala FS, Bertin J, Koller BH, Liu Z, Ting JP: Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity. J Immunol 2010; 185: 4515-4519.
57. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA: NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356: 1216-1225. (Pubitemid 46465597)
58. Alkhateeb A, Qarqaz F: Genetic association of NALP1 with generalized vitiligo in Jordanian Arabs. Arch Dermatol Res 2010; 302: 631-634.
59. Jin Y, Birlea SA, Fain PR, Spritz RA: Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 2007; 127: 2558-2562. (Pubitemid 47585070)
60. Ueta M, Sotozono C, Inatomi T, Kojima K, Tashiro K, Hamuro J, Kinoshita S: Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 2007; 91: 962-965. (Pubitemid 47013114)
61. Turan H, Bulbul BE, Yakut T, Karkucak M, Tunali S, Saricaoglu H: Toll-like receptor 9 polymorphism in patients with erythema multiforme, Stevens-Johnson syndrome and Stevens Johnson syndrome/toxic epidermal necrolysis overlap syndrome. Bratisl Lek Listy 2011; 112: 260-263.
62. Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease ( * ). Annu Rev Immunol 2009; 27: 621-668.
63. Henderson C, Goldbach-Mansky R: Monogenic autoinflammatory diseases: New insights into clinical aspects and pathogenesis. Curr Opin Rheumatol 2010; 22: 567-578.
64. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr., Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, Moore TL, Schikler K, Hoffman H, Lovell DJ, Lipnick R, Barron K, O'Shea JJ, Kastner DL, Goldbach-Mansky R: De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-3348. (Pubitemid 35453546)
65. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-305. (Pubitemid 33096455)
66. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J: NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-325. (Pubitemid 38388233)
67. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, Anderson JP, Wanderer AA, Firestein GS: Prevention of coldassociated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779-1785. (Pubitemid 39488063)
68. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ: Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-2452.
69. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-2425.
70. Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, Grimprel E, Landman-Parker J, Hentgen V, Marlin S, McElreavey K, Sarkisian T, Grateau G, Alnemri ES, Amselem S: Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 2008; 105: 1614-1619. (Pubitemid 351346563)
71. Borghini S, Tassi S, Chiesa S, Caroli F, Carta S, Caorsi R, Fiore M, Delfino L, Lasiglie D, Ferraris C, Traggiai E, Di Duca M, Santamaria G, D'Osualdo A, Tosca M, Martini A, Ceccherini I, Rubartelli A, Gattorno M: Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 2011; 63: 830-839.
72. Jeru I, Le Borgne G, Cochet E, Hayrapetyan H, Duquesnoy P, Grateau G, Morali A, Sarkisian T, Amselem S: Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes. Arthritis Rheum 2011; 63: 1459-1464.
73. Lich JD, Williams KL, Moore CB, Arthur JC, Davis BK, Taxman DJ, Ting JP: Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J Immunol 2007; 178: 1256-1260. (Pubitemid 46154594)
74. Jeru I, Hentgen V, Normand S, Duquesnoy P, Cochet E, Delwail A, Grateau G, Marlin S, Amselem S, Lecron JC: Role of interleukin-1beta in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. Arthritis Rheum 2011; 63: 2142-2148.
75. Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, Yamazaki S, Saito M, Yoshioka T, Kawai T, Sakai H, Tanizaki H, Heike T, Miyachi Y, Nakahata T: Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009; 60: 242-250.
76. Magalhaes JG, Sorbara MT, Girardin SE, Philpott DJ: What is new with Nods? Curr Opin Immunol 2011; 23: 29-34.
77. Chen G, Shaw MH, Kim YG, Nunez G: NOD-like receptors: Role in innate immunity and inflammatory disease. Annu Rev Pathol 2009; 4: 365-398.
78. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241. (Pubitemid 43372104)
79. So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
80. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A: The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68: 1613-1617.
81. Ahmad T, Zhang L, Gogus F, Verity D, Wallace G, Madanat W, Fayyad F, James T, Neville M, Kanawati C, Fortune F, Celik A, Stanford M, Jewell DP, Marshall SE: CARD15 polymorphisms in Behcet's disease. Scand J Rheumatol 2005; 34: 233-237.
82. Uyar FA, Saruhan-Direskeneli G, Gul A: Common Crohn's disease-predisposing variants of the CARD15/NOD2 gene are not associated with Behcet's disease in Turkey. Clin Exp Rheumatol 2004; 22:S50-S52.
83. Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, Laman JD, Kuijpers RW, Baarsma GS, Stanford MR, Fortune F, Madanat W, van Hagen PM, van Laar JA: Low prevalence of NOD2 SNPs in Behcet's disease suggests protective association in Caucasians. Rheumatology (Oxford) 2009; 48: 1375-1377.
84. Bacanli A, Sallakci N, Yavuzer U, Alpsoy E, Yegin O: Toll-like receptor 2 Arg753Gln gene polymorphism in Turkish patients with Behcet's disease. Clin Exp Dermatol 2006; 31: 699-701. (Pubitemid 44086803)
85. Cosan F, Oku B, Cakiris A, Duymaz-Tozkir J, Mercanoglu F, Saruhan-Direskeneli G, Ustek D, Gul A: No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behcet's disease. Clin Rheumatol 2009; 28: 1385-1388.
86. Durrani O, Banahan K, Sheedy FJ, McBride L, Ben-Chetrit E, Greiner K, Vaughan RW, Kondeatis E, Hamburger J, Fortune F, Stanford MR, Murray PI, O'Neill LA, Wallace GR: TIRAP Ser180Leu polymorphism is associated with Behcet's disease. Rheumatology (Oxford) 2011; 50: 1760-1765.
87. Ben Dhifallah I, Lachheb J, Houman H, Hamzaoui K: Toll-like-receptor gene polymorphisms in a Tunisian population with Behcet's disease. Clin Exp Rheumatol 2009; 27:S58-S62.
88. Boiardi L, Atzeni F, Casali B, Farnetti E, Nicoli D, Pipitone N, Catanoso MG, Olivieri I, Cantini F, Salvi F, La CR, Triolo G, Filippini D, Paolazzi G, Salvarani C: Toll-like receptor 4 (TLR4) gene polymorphisms in Italian patients with Behcet's disease. Clin Exp Rheumatol 2009; 27:S43-S47.
89. Horie Y, Meguro A, Ota M, Kitaichi N, Katsuyama Y, Takemoto Y, Namba K, Yoshida K, Song YW, Park KS, Lee EB, Inoko H, Mizuki N, Ohno S: Association of TLR4 polymorphisms with Behcet's disease in a Korean population. Rheumatology (Oxford) 2009; 48: 638-642.
90. Drexler SK, Foxwell BM: The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 2010; 42: 506-518.
91. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202: 1131-1139. (Pubitemid 41464506)
92. Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, Barrat FJ: Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010; 207: 2931-2942.
93. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD: Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 407-417. (Pubitemid 40385482)
94. Yu P, Musette P, Peng SL: Toll-like receptor 9 in murine lupus: More friend than foe! Immunobiology 2008; 213: 151-157. (Pubitemid 351164231)
95. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV: TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203: 553-561.
96. Wu X, Peng SL: Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 2006; 54: 336-342. (Pubitemid 43122217)
97. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, Shlomchik MJ: TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010; 184: 1840-1848.
98. Zhou XJ, Lv JC, Cheng WR, Yu L, Zhao MH, Zhang H: Association of TLR9 gene polymorphisms with lupus nephritis in a Chinese Han population. Clin Exp Rheumatol 2010; 28: 397-400.
99. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: Implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54: 3601-3611. (Pubitemid 44737172)
100. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-496. (Pubitemid 46605917)
101. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290:C917-C924.
102. Ulloa L, Messmer D: High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine Growth Factor Rev 2006; 17: 189-201. (Pubitemid 43949075)
103. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE: Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: Implications for the pathogenesis of SLE. J Exp Med 2008; 205: 3007-3018.
104. Patole PS, Pawar RD, Lichtnekert J, Lech M, Kulkarni OP, Ramanjaneyulu A, Segerer S, Anders HJ: Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun 2007; 29: 52-59. (Pubitemid 47016916)
105. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly KM, Reeves WH, Bauer S, Krieg AM: Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Tolllike receptors 7 and 8. J Exp Med 2005; 202: 1575-1585. (Pubitemid 41746603)
106. Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, Flavell RA, Bolland S: Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007; 27: 801-810. (Pubitemid 350102256)
107. Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, Maki N, Hatakeyama T, Sawada K: Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008; 152: 482-487. (Pubitemid 351661498)
108. Hawn TR, Wu H, Grossman JM, Hahn BH, Tsao BP, Aderem A: A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci USA 2005; 102: 10593-10597. (Pubitemid 41061599)
109. Furnrohr BG, Wach S, Kelly JA, Haslbeck M, Weber CK, Stach CM, Hueber AJ, Graef D, Spriewald BM, Manger K, Herrmann M, Kaufman KM, Frank SG, Goodmon E, James JA, Schett G, Winkler TH, Harley JB, Voll RE: Polymorphisms in the Hsp70 gene locus are genetically associated with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 1983-1989.
110. Vargas-Alarcon G, Granados J, Martinez-Laso J, Gomez-Casado E, Zuniga J, Salgado N, Hernandez-Pacheco G, Hesiquio R, Rodriguez-Reyna TS, Gamboa R, Alcocer-Varela J, Arnaiz-Villena A: Lack of association between the polymorphism at the heatshock protein (HSP70-2) gene and systemic lupus erythematosus (SLE) in the Mexican mestizo population. Genes Immun 2000; 1: 367-370.
111. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK: Novel signal transduction pathway utilized by extracellular HSP70: Role of tolllike receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277: 15028-15034. (Pubitemid 34952579)
112. Mathur S, Walley KR, Wang Y, Indrambarya T, Boyd JH: Extracellular heat shock protein 70 induces cardiomyocyte inflammation and contractile dysfunction via TLR2. Circ J 2011; 75: 2445-2452.
113. Tsan MF, Gao B: Heat shock proteins and immune system. J Leukoc Biol 2009; 85: 905-910.
114. Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlondorff D, Anders HJ: Viral doublestranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005; 16: 1326-1338. (Pubitemid 41716517)
115. Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM: TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008; 8: 541-544.
116. Kimkong I, Avihingsanon Y, Hirankarn N: Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by realtime RT-PCR. Lupus 2009; 18: 1066-1072.
117. Murphy S, Nguyen VH: Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma 2011; 52: 1844-1856.
118. Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R, Ottinger H, Rath PM, Ross RS, Roggendorf M, Grosse-Wilde H, Beelen DW: Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 2006; 81: 247-254.
119. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, Hahn J, Eissner G, Scholmerich J, Andreesen R: Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104: 889-894. (Pubitemid 38970589)
120. Penack O, Smith OM, Cunningham-Bussel A, Liu X, Rao U, Yim N, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Brandl K, van den Brink MR: NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med 2009; 206: 2101-2110.
121. Sato H, Williams HR, Spagnolo P, Abdallah A, Ahmad T, Orchard TR, Copley SJ, Desai SR, Wells AU, du Bois RM, Welsh KI: CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. Eur Respir J 2010; 35: 324-330.
122. Martin TM, Doyle TM, Smith JR, Dinulescu D, Rust K, Rosenbaum JT: Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 2003; 136: 933-935. (Pubitemid 37330047)
123. Tanabe T, Ishige I, Suzuki Y, Aita Y, Furukawa A, Ishige Y, Uchida K, Suzuki T, Takemura T, Ikushima S, Oritsu M, Yokoyama T, Fujimoto Y, Fukase K, Inohara N, Nunez G, Eishi Y: Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. Biochim Biophys Acta 2006; 1762: 794-801. (Pubitemid 44403051)
124. de Koning HD, Bodar EJ, van der Meer JW, Simon A: Schnitzler syndrome: Beyond the case reports: Review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-148. (Pubitemid 350151505)
125. Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A: IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 2008; 121: 260-262.
126. de Koning HD, Schalkwijk J, van der Meer JW, Simon A: Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011; 128: 1352-1354.
127. Loock J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross WL: Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol 2010; 125: 500-502.
128. de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW: Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis 2006; 65: 542-544.
129. Gran JT, Midtvedt O, Haug S, Aukrust P: Treatment of Schnitzler's syndrome with anakinra: Report of three cases and review of the literature. Scand J Rheumatol 2011; 40: 74-79.
130. Buchau AS, Schauber J, Hultsch T, Stuetz A, Gallo RL: Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol 2008; 128: 2646-2654.
131. Vollmer J, Krieg AM: Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61: 195-204.
132. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R: Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.
133. Sato T, Yamamoto M, Shimosato T, Klinman DM: Accelerated wound healing mediated by activation of Toll-like receptor 9. Wound Repair Regen 2010; 18: 586-593.
134. Yamamoto M, Sato T, Beren J, Verthelyi D, Klinman DM: The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides. Biomaterials 2011; 32: 4238-4242.
135. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL: Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37: 3582-3586.
136. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, Punaro M, Bolland S, Soumelis V, Banchereau J, Coffman RL, Pascual V, Barrat FJ: TLR recognition of self-nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465: 937-941.
137. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200. (Pubitemid 34141451)
138. Schon MP, Schon M: TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27: 190-199.
139. Lacarrubba F, Potenza MC, Gurgone S, Micali G: Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: A case series and review. J Dermatolog Treat 2011; 22: 353-358.
140. Micali G, Lacarrubba F, Dinotta F, Massimino D, Nasca MR: Treating skin cancer with topical cream. Expert Opin Pharmacother 2010; 11: 1515-1527.
141. Ganjian S, Ourian AJ, Shamtoub G, Wu JJ, Murase JE: Off-label indications for imiquimod. Dermatol Online J 2009; 15: 4.
142. Valins W, Amini S, Berman B: The expression of toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical toll-like receptor modulators. J Clin Aesthet Dermatol 2010; 3: 20-29.
143. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, Wagner TL, Tomai MA: Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58: 365-372.
144. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, Miller RL, Sauder DN: Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141. (Pubitemid 30195986)
145. Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, Gilliet M: Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97: 1143-1153. (Pubitemid 41511214)
146. Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC: A phase II doseranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008; 159: 205-210. (Pubitemid 351874499)
147. Fife KH, Meng TC, Ferris DG, Liu P: Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. Antimicrob Agents Chemother 2008; 52: 477-482. (Pubitemid 351170817)
148. Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, Slade HB, Tyring SK, Warren T, Sacks SL, Leone P, Bergland VA, Wald A: Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: A randomized, controlled trial. J Infect Dis 2007; 195: 1324-1331. (Pubitemid 46649619)
149. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM, Miller JF: The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005; 175: 1983-1990. (Pubitemid 41023106)
150. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N: Immunization of malignant melanoma patients with full-length NYESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008; 181: 776-784.
151. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, Dietrich H, Lipford G, Takeda K, Akira S, Wagner H, Bauer S: The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33: 2987-2997. (Pubitemid 37428331)
152. Dzopalic T, Dragicevic A, Vasilijic S, Vucevic D, Majstorovic I, Bozic B, Balint B, Colic M: Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1-and Th-17-polarizing capability. Int Immunopharmacol 2010; 10: 1428-1433.
153. Agarwala SS, Kirkwood JM, Bryant J: Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther 2000; 6: 171-176. (Pubitemid 32834916)
154. Krieg AM: Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-1194. (Pubitemid 46718403)
155. Krieg AM: Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-167.
156. Najar HM, Dutz JP: Topical CpG enhances the response of murine malignant melanoma to dacarbazine. J Invest Dermatol 2008; 128: 2204-2210.
157. So EY, Ouchi T: The application of Toll-like receptors for cancer therapy. Int J Biol Sci 2010; 6: 675-681.